Sandwich ELISA: To detect hIGF-BP7 (using 100 μL/well antibody solution) a concentrationof 0.5-2.0 μg/mL of this antibody is required. In conjunction with Biotinylated Anti-HumanIGF-BP7 (ABIN181539 or ABIN181540) as a detection antibody, it allows the detection ofat least 0.2-0.4 ng/well of recombinant hIGF-BP7. Western blot: To detect hIGF-BP7 this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit forrecombinant hIGF-BP7 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
限制
仅限研究用
溶解方式
Restore in sterile water to a concentration of 0.1-1.0 mg/mL.
缓冲液
PBS, pH 7.2
注意事项
Avoid repeated freezing and thawing.
储存条件
4 °C/-20 °C
储存方法
The lyophilized antibody is stable at -20 °C for one year from despatch. The reconstituted antibody is stable for two weeks at 2-8 °C. Frozen aliquots are stable for six months when stored at -20 °C.
有效期
12 months
抗原
IGFBP7
(Insulin-Like Growth Factor Binding Protein 7 (IGFBP7))
IGF-BPs form high affinity complexes with both IGF-I and IGF-II and act to control of the distribution, function and activity of IGFs in various cell tissues and body fluids. There are seven named IGF-BPs. IGFBP7 plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGFBP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. IGFBP7 is expressed in a wide range of normal human tissues and it usually shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.Synonyms: IBP-7, IBP7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, Insulin-like growth factor-binding protein 7, MAC25, PGI2-stimulating factor, PSF, Prostacyclin-stimulating factor, TAF, Tumor-derived adhesion factor